EUROAPI to Invest €50 Million at Its Budapest Site to Meet the Growing Demand for Prostaglandins

Regulatory News:

EUROAPI (Paris:EAPI) announces a €50 million capex investment for the installation of a new state-of-the-art production plant at its Budapest site. The project will be focused on the debottlenecking of the current capacity and the construction of new multi-purpose manufacturing equipment that will more than double the overall prostaglandin capacity of the Budapest site by 2027 in two phases: 2023-2025 (approximately 2/3 of the total investment) and 2026-2027.

Prostaglandin is one of the most dynamic components of the active pharmaceutical ingredient (API) market, with a € ~5 billion annual drug product sales market, expected to grow at 5-7% annually (CAGR¹) between 2022 and 2027².

EUROAPI is the only Western supplier with a complete portfolio of prostaglandins and a fully integrated production site located in Europe. This project will bolster EUROAPI’s Hungarian operations and reinforce the company’s commitment to serving the needs of its clients in differentiated segments of health products.

“EUROAPI is positioned as the only Western prostaglandin supplier with a complete prostaglandin portfolio and a fully backward-integrated production located in the heart of Europe. This key investment in Budapest will enable us to increase our productivity and meet the growing demand in a dynamic prostaglandin market, growing at 5-7% per annum,” said Karl Rotthier, Chief Executive Officer of EUROAPI.

This investment should enable EUROAPI to reduce its environmental footprint thanks to a modern air handling system that will lower the energy consumption of the new workshop. The production plant will also be equipped with solar panels and a fully closed waste handling system. It will feature highly potent-API (HP-API) capabilities for potential further developments.

About EUROAPI

EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

Taking action for health by enabling access to essential therapies inspires our 3,450 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn.